-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2260 Igh Translocation with Undefined Partners Is Associated with Superior Outcome in Multiple Myeloma Patients

Program: Oral and Poster Abstracts
Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster II
Hematology Disease Topics & Pathways:
multiple myeloma, Diseases, Plasma Cell Disorders, Lymphoid Malignancies, Clinically relevant
Sunday, December 6, 2020, 7:00 AM-3:30 PM

Xue-Han Mao, MD1*, Yan Xu, MD2,3*, Yuting Yan4*, Junling Zhuang, MD, PhD5*, Huishou Fan4*, Weiwei Sui4*, Jiahui Liu4*, Shuhui Deng, MD4*, Shuhua Yi, MD6*, Lugui Qiu, MD4 and Gang An7*

1Institute of Hematology & Blood Diseases Hospital, TIANJIN, China
2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
3Institute of Hematology & Blood Diseases Hospital, Chinese Academic Medical Science & Peking Union Medical College, Tianjin, China
4National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
5Peking Union Medical Colleague Hospital, Nashville, TN
6National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, Duarte, CA
7lymphoma and myeloma center, National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

Background: In multiple myeloma (MM), impact of specific chromosomal translocations involving IgH (14q21 locus, including t(4;14), t(11;14), and t(14;16) etc.) has been explored extensively. However, over 15% MM patients harboring IgH translocation with undefined partners have long been ignored.

Methods: A prospective non-randomized cohort study with a total of 715 newly-diagnosed MM cases was conducted, 13.6% of whom were t(14;undefined) positive. The whole cohort was divided into four groups: no IgH split (47.7%); t(14;undefined) (13.6%); t(11;14) (17.6%); and t(4;14) or t(14;16) group (21.1%).

Results: Median OS for the four groups were 84.2, not reached (NR), 58.7, and 44.2 months respectively, with p values for t(14;undefined) vs. no IgH split, t(11;14), and t(4;14)/t(14;16) groups of 0.197, 0.022 and 0.001, respectively(Figure B).In bortezomib-based group, the survival advantage gained by t(14;undefined) group was much more significant compared to t(11;14) and t(4;14)/t(14;16) groups. Importantly, t(14;undefined) turned out to be an independent predictive factor for longer OS of MM patients in multivariate analysis, especially in the context of bortezomib-treatment. Similar results were also observed in the PUMCH external validation cohort (Figure C).

Conclusion: Collectively, our data confirmed and externally validated the favorable prognosis of the t(14;undefined) groups, especially in the era of novel agents.

Disclosures: No relevant conflicts of interest to declare.

See more of: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster II
See more of: Oral and Poster Abstracts
<< Previous Abstract | Next Abstract >>
*signifies non-member of ASH